Leptin: A Marker for AML Chemo-Sensitivity

Recruiting now

Conditions studied: AML, Adult

In brief

Acute Myeloid Leukemia (AML) is a malignant clonal disorder of hematopoietic stem/progenitor cells, with a five-year survival rate of approximately 30%. Chemotherapy resistance and relapse remain major challenges. Increased bone marrow adipocytes contribute to AML cell drug resistance.This study found that elevated levels of the adipokine leptin enhance oxidative phosphorylation (OXPHOS) in AML cells, accompanied by increased mitochondrial reactive oxygen species (mtROS), which stimulates antioxidant capacity and thereby induces chemotherapy resistance. By establishing a correlation between leptin levels in bone marrow supernatant and clinical outcomes in AML patients, this research provides novel strategic insights for targeting drug resistance and improving prognostic evaluation.

Key facts

Study ID

NCT07163728

Run by

Fujian Medical University Union Hospital

People needed

86

Starts

2025-08-01

Expected to finish

2026-12-31

Last updated by the study team

2025-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)";
• All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;
• Patients participate in the study accompanied by family members and sign informed consent documents.

You may not qualify if…

• Patients with concurrent malignancies requiring treatment;
• Presence of infectious diseases, including SARS, viral hepatitis, or HIV/ AIDS;
• Major surgery performed within the last 21 days;
• Performance Status (PS) score >3;
• Severe liver or kidney dysfunction or serious infection;
• Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.

Where it is running

• Fujian Medical University Union Hospital — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.